Supply chain decarbonization & supplier engagement (Scope-3 reduction)
21 January 2026
No Comments
Introduction Many companies have reduced direct emissions from operations and purchased energy. Scope 3
Issue: Vol. 43
Enzyme-based synthesis: A sustainable revolution in RNA therapeutics manufacturing
21 January 2026
No Comments
RNA-based therapies have rapidly emerged as a breakthrough in medicine, holding considerable promise for
Advancing Peptide Synthesis: Riding the Wave of GLP-1 Drug Success
21 January 2026
No Comments
Introduction Peptide therapeutics have emerged as a critical class of pharmaceuticals, with over
Susan LI, Peptide Chief Scientist – Asymchem
21 January 2026
No Comments
Susan Li holds a PhD in Polymer Chemistry and Physics from Nankai University and
PEER REVIEWED – Conduction Heating-Assisted Solid-Phase Peptide Synthesis
21 January 2026
No Comments
Introduction Peptides are an important kind of biomolecule with an increasing importance in
Biologically Active Truncated Glycopeptides Derived from Pituitary Adenylate Cyclase Activating Polypeptide
21 January 2026
No Comments
Introduction: Background and Significance of PACAP With the massive success of Semaglutide and related
The continuous evolution of Tides manufacturing excellence
21 January 2026
No Comments
Peptides and oligonucleotides (TIDES) are transforming modern medicine by precisely targeting disease pathways, expanding
Patient Centricity as the Foundation of Pharmaceutical Innovation
21 January 2026
No Comments
Negativity. Sadly, that seems to be the single word to describe the popular view
Safeguarding every R&D sample: how sustainable storage and smart scalability keep research viable
6 October 2025
No Comments
This article examines the critical importance of sustainable and scalable sample storage in safeguarding R&D samples for pharmaceutical, biotech, and CDMO organizations. It highlights how overlooked storage risks — from outdated infrastructure to regulatory gaps and transport failures — can compromise sample viability, delay research timelines, and drive up costs. The article aims to show that integrated sample stability and biorepository management should be proactive, requiring robust systems, smart cold chain logistics, disaster recovery planning, and clear data traceability. By reassessing internal capabilities and strategically outsourcing when appropriate, companies can protect their research investments and ensure continued innovation and compliance.
Bridging the Gap: How Pre-Formulation and Strategies Enable Scalable PROTAC Development
6 October 2025
No Comments
Proteolysis-targeting chimeras (PROTACs) hold considerable potential for the treatment of diseases such as cancer. Following their first publication in 2001, their development has rapidly progressed, with some now reaching Phase III trials. However, developing PROTACs successfully requires a robust, multidisciplinary framework, especially during pre-formulation and analytical development.
This article examines the basic mechanisms and characteristics of PROTACs, highlighting the importance of early-phase formulation decisions during development. Additionally, solid form and solubility strategies for maximizing ease of formulation, including particle engineering and amorphous solid dispersions (ASDs), are also explored. Finally, the article highlights the vital role of contract development and manufacturing organizations (CDMOs) in leveraging handling capabilities and technical know-how to help innovators unlock the full potential of these novel molecules.